Together, these data support the notion that SIK2 inhibitor ARN‐3236 could significantly enhance the sensitivity of radiotherapy both in vitro and in vivo, suggesting its potential as an effective strategy to overcome CRC radioresistance. Here, SIK2 is linked to colorectal carcinoma.